Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Second Impact Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    97 result(s) found for: Second Impact Syndrome. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2011-006090-25 Sponsor Protocol Number: GARBK8273 Start Date*: 2012-03-06
    Sponsor Name:Tartu Ülikooli kardioloogiakliinik
    Full Title: The Impact of Heart Rate on Central Hemodynamics of Antihypertensive Therapy
    Medical condition: Patients with dual chamber (atrium and ventricle) cardiac pacemaker placed due to sick sinus syndrome (at least 1 month after implantation)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10053103 Heart rate and pulse investigations HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004143-13 Sponsor Protocol Number: SHP-609-302 Start Date*: 2015-03-19
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome...
    Medical condition: Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    20.0 10010331 - Congenital, familial and genetic disorders 10056917 Hunter's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000592-33 Sponsor Protocol Number: N/A Start Date*: 2006-03-02
    Sponsor Name:Gentium S.p.A [...]
    1. Gentium S.p.A
    2. EBMT Trial Office
    Full Title: Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation
    Medical condition: Hepatic veno-occlusive disease following hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047217 Venoocclusive syndrome of the liver LLT
    9.1 10047207 Veno-occlusive liver damage LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) GB (Completed) AT (Completed) IT (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002186-34 Sponsor Protocol Number: MP_COVID19 Start Date*: 2020-06-03
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR).
    Full Title: Efficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS) in COVID-19
    Medical condition: COVID-19 Pneunomia (SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001830-32 Sponsor Protocol Number: RC31/17/0448 Start Date*: 2019-12-18
    Sponsor Name:University Hospital Toulouse
    Full Title: Phase III Trial to assess impact of ultra-long versus long down-regulation protocol on IVF/ICSI outcomes in infertile women presenting with adenomyosis.
    Medical condition: Infertilty in women with adenomyosis.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001968-28 Sponsor Protocol Number: 19385A Start Date*: 2022-02-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache
    Medical condition: Chronic cluster headache
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) DK (Completed) NL (Completed) FI (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006048-29 Sponsor Protocol Number: INjECT Start Date*: 2022-02-21
    Sponsor Name:AOU MATERDOMINI
    Full Title: BotulInum toxin type A for peripheral Neuropathic pain in subjEcts with Carpal Tunnel syndrome: a multicenter, randomized, double-blind, placebo-controlled study
    Medical condition: Peripheral neuropathic pain in subjects with carpal tunnel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10007698 Carpel tunnel syndrome LLT
    20.0 100000004852 10077974 Peripheral neuropathic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006291-38 Sponsor Protocol Number: 06-010 Start Date*: 2007-10-02
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048439 Fibromyalgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Ongoing) NL (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003400-39 Sponsor Protocol Number: NGLU-CL02 Start Date*: 2014-07-15
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
    Medical condition: Mucopolysaccharidosis III, type B (MPS IIIB), Sanfilippo B
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10056918 Sanfilippo's syndrome LLT
    19.0 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2022-002314-17 Sponsor Protocol Number: JR-441-101 Start Date*: 2023-07-03
    Sponsor Name:JCR Pharmaceuticals Co., Ltd.
    Full Title: Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA
    Medical condition: Mucopolysaccharidosis type IIIA (MPS IIIA) MPS III is an autosomal recessive disease characterized by the accumulation of HS in the tissues throughout the body due to a deficiency in enzymes involv...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002480-19 Sponsor Protocol Number: A0081275 Start Date*: 2012-01-20
    Sponsor Name:PFIZER, SLU
    Full Title: A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, 2-WAY CROSSOVER STUDY OF PREGABALIN IN THE TREATMENT OF FIBROMYALGIA WITH CONCURRENT ANTIDEPRESSANT THERAPY FOR COMORBID DEPRES...
    Medical condition: This study will be conducted in subjects with fibromyalgia. Subjects will also be on concurrent medication for comorbid depression.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001205-73 Sponsor Protocol Number: IMP4297-202 Start Date*: 2021-08-24
    Sponsor Name:IMPACT Therapeutics, Inc.
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib Maintenance in mCRPC Patients with Homologous Recombination Repair Gene Alterations after Docetax...
    Medical condition: metastatic castration-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) FR (Ongoing) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000620-34 Sponsor Protocol Number: Imatinib-MS Start Date*: 2018-04-24
    Sponsor Name:Department of Clinical Neuroscience, Karolinska Institutet
    Full Title: Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study
    Medical condition: Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where ther...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.0 10029205 - Nervous system disorders 10028247 Multiple sclerosis like syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000630-22 Sponsor Protocol Number: TV50717-CNS-30047 Start Date*: 2018-06-05
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children a...
    Medical condition: Tics associated with Tourette Syndrome(TS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Completed) FR (Completed) NL (Ongoing) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002116-14 Sponsor Protocol Number: CCTL019G2201J Start Date*: 2018-10-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive...
    Medical condition: Pediatric and young adult patients aged 1 to 25 years with first-line NCI high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) who are in CR1 with minimal residual disease (MRD) positive (MR...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) DK (Trial now transitioned) FR (Ongoing) IT (Restarted) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) NL (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002051-42 Sponsor Protocol Number: R119861 Start Date*: 2019-10-25
    Sponsor Name:University of Manchester
    Full Title: A phase I-II, study of autologous CD34+ haematopoietic stem cells transduced ex vivo with CD11b lentiviral vector encoding for human SGSH in patients with mucopolysaccharidosis type IIIA (MPS IIIA,...
    Medical condition: MPS IIIA, mucopolysaccharidosis type IIIA
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028093 Mucopolysaccharidosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003139-47 Sponsor Protocol Number: EFC15992 Start Date*: 2021-06-17
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smo...
    Medical condition: Smoldering Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) SE (Completed) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) DE (Trial now transitioned) LT (Trial now transitioned) HU (Ongoing) FR (Ongoing) GR (Trial now transitioned) IE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004285-34 Sponsor Protocol Number: STH20370 Start Date*: 2019-01-18
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: The impact of aspirin dose modification on the innate immune response - WILL lOWer dose aspirin Therapy ReducE the response to Endotoxin? – (WILLOW TREE)
    Medical condition: Acute coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002746-21 Sponsor Protocol Number: GELTAMO18-HL Start Date*: 2020-04-29
    Sponsor Name:Fundación GELTAMO
    Full Title: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentux...
    Medical condition: Patients with Relapsed /Refractory Classical Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003400-13 Sponsor Protocol Number: BST003 Start Date*: 2021-01-19
    Sponsor Name:Groupe Francophone des Myélodysplasies (GFM)
    Full Title: A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Mye...
    Medical condition: Patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA